Enhancing the recognition on the clinical implication of lipoprotein (a) and improving the management strategy of residual cardiovascular risk.
10.3760/cma.j.cn112148-20220205-00087
- Author:
Jian Jun LI
1
Author Information
1. Cardiometabolic Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China.
- Publication Type:Journal Article
- MeSH:
Cardiovascular Diseases;
Cholesterol, LDL;
Heart Disease Risk Factors;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Lipoprotein(a);
Risk Factors
- From:
Chinese Journal of Cardiology
2022;50(7):715-716
- CountryChina
- Language:Chinese
